The Infectious Disease Research Institute will use these technologies through a nonexclusive license.

3M Drug Delivery Systems signed a nonexclusive license agreement with the Infectious Disease Research Institute (IDRI) to advance vaccine research in developing countries.

3M will donate its patented toll-like receptor (TLR) immune-response modifier compounds and its needle-free microstructured transdermal delivery system. IDRI will use the compounds, which are vaccine adjuvants, for research into new vaccines.

3M’s TLR compounds, TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery and ease in manufacturing, according to the company.

Previous articleNovavax Opens Infectious Disease Vaccine Plant in Maryland
Next articleScientists Uncover p53’s Role in Effectiveness of IGF-1 Inhibitors in Prostate Cancer